Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03462719
Title	A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW)
Acronym	GLOW
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Janssen Research & Development, LLC
Indications	chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma
Therapies	Chlorambucil + Obinutuzumab Ibrutinib + Venetoclax
Age Groups:	senior \| adult
Covered Countries	USA \| NLD \| GBR \| FRA \| ESP \| CAN \| BEL